Investment banking firm Jefferies raises Eli Lilly's price target based on optimism over orfoscerinib, indicating strong confidence in its potential. ...
Class action lawsuit filed against Amylyx Pharmaceuticals for securities violations, alleging overstated drug prospects and failure to disclose key information. ...